Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 20.01K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -1.08M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -99.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 667.16M | 52W Low Chg | - |
| Insider Own | - | ROA | -888.76% | Shares Float | - | Beta | -23.01 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00000 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | - | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 800 | Change | 0.00% |
About PATHFINDER CELL THERAPY INC
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.